Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants

A Phase 1, Open-label, Randomized, 3-Period, 2-Sequence, Crossover Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants

This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.

Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.

This will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers.

The main questions it aims to answer is:

1. Does food or a PPI change how the body absorbs a single dose of VRN101099?
2. Is a single dose of VRN101099 safe and well tolerated when taken with or without food or a PPI?
3. How is VRN101099 removed through urine when taken with or without food or a PPI?

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy Adult
• Intervention / Treatment: Drug: VRN101099

Detailed Description

This is a single-centre, 3-period, 2-sequence, open-label, randomized, crossover study to evaluate the effect of food and a PPI on the PK of a 160 mg oral dose of VRN101099 in healthy adult participants. The study will consist of approximately 24 participants, who will be enrolled and then randomized 1:1 into 2 cohorts (sequences).

This is a 3-period, 2-sequence, crossover study, which means every participant will receive VRN101099 three times-once in each condition, but in different orders depending on their assigned sequence.

Participants will be randomly assigned to one of two sequences:

Sequence 1: Fasted → Fed → Fed + PPI Sequence 2: Fed → Fasted → Fasted + PPI

All participants will take the same dose of VRN101099, but under different conditions:

• once after eating a meal,
• once while taking a PPI,
• and once on an empty stomach.

Each dose of VRN101099 will be 160 mg and taken once per period. There will be at least 7 days of washout between doses.

Blood samples may be taken up to 240 hours (10 days) after each dose to measure drug levels

Urine samples will be collected for 24 hours after each dose

Participants will be monitored for side effects and general safety throughout the study.

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Anne Clark; Phone Number: +19 19-434-8892; Email: a.clark@voronoi.io

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Nucleus Network
      • Contact: Dr. Victor Wong; Phone Number: 03 85939801; Email: v.wong@nucleusnetwork.com.au
      • Principal Investigator: Dr. Victor Wong

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male or female aged between 18 and 65 years of age (inclusive at the time of informed consent).
2. In good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and/or before the first administration of IP (at the discretion of the PI or designee).
3. BMI between ≥ 18.0 and ≤ 32.0 kg/m2 and weight ≥ 50 kg at Screening.
4. Clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.
5. Female participants must be either not of childbearing potential or if they are a woman of childbearing potential and are engaged in heterosexual intercourse, they must agree to use an acceptable, highly effective contraception method in conjunction with a condom for the male partner from Screening until 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).
6. Male participants must not be of childbearing potential, or if they are engaged in sexual relations with WOCBP, they must agree to use a condom in conjunction with an acceptable, highly effective contraception method for the female partner from Screening until 100 days after the last dose of the IP.
7. Males must not donate sperm and females must not donate ova from the first dose of IP until at least 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).
8. Able and willing to attend the necessary visits to the CRU.
9. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.

Exclusion Criteria:

1. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make it unlikely for the participant to comply with the protocol or complete the study per protocol. This includes but may not be limited to: medical histories (eg, hepatic/biliary, renal, cardiovascular, endocrine, respiratory, digestive, haematologic, oncologic [except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to the first administration of IP], central nervous system, psychiatric, musculoskeletal) or past medical/surgical histories that may affect drug absorption, distribution, metabolism, or excretion (excluding simple appendectomy or herniorrhaphy).
2. Participants with known or suspected conditions or significant gastrointestinal disorders that may interfere with drug absorption (eg, inflammatory bowel disease, chronic diarhoea, malabsorption syndromes, or prior gastrointestinal surgery affecting absorption).
3. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.
4. History of hypersensitivity and/or intolerance to PPIs.
5. History of infections requiring parenteral antibiotics within 6 months prior to the first administration of IP.
6. Blood donations of ≥ 400 mL or significant blood loss within 60 days prior to the first administration of investigational product (IP), plasma donation within 7 days prior to the first administration of IP, or platelet donation within 30 days prior to the first administration of IP. Participants must also agree not to donate blood, plasma, or platelets during the study and for at least 30 days after the last dose of IP.
7. Abnormal findings on 12-lead (triplicate) ECG at Screening that are considered by the PI or designee to be clinically significant; or has a QTcF (Fridericia's formula) interval at Screening of > 450 msec for males or > 470 msec for females based on the average of the 3 readings. Repeat testing at Screening is acceptable for abnormal values at the discretion of the Investigator (once per parameter).
8. Abnormal vital sign findings at Screening that are considered clinically significant by the Principal Investigator (PI) or designee, including systolic blood pressure >140 mmHg or < 90 mmHg, diastolic blood pressure > 90 mmHg or < 50 mmHg, or a history of symptomatic hypotension. If a screening value falls outside these limits, repeat measurement is permitted at the discretion of the Investigator, with one repeat assessment allowed per parameter. Eligibility should be based on the repeat value.
9. Active liver disease, or AST and/or ALT > 1.5 × upper limit of normal at Screening. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.
10. Estimated glomerular filtration rate (eGFR) of ≤ 80 mL/min/ 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula.
11. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening.
12. Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device), within 14 days prior to the first administration of the IP; or use of any over the counter medication, herbal remedies, supplements, or vitamins within 7 days prior to the first administration of IP and during course of study. Note: Simple analgesia (eg, paracetamol) may be permitted at the discretion of the PI, provided they are used within the recommended maximum daily doses as specified in the package insert.
13. Use of any drugs, herbal supplements, or foods that are known to be strong or moderate inhibitors/inducers of CYP3A4 (eg, carbamazepine, rifampin, St. John's wort, ketoconazole, ginkgo biloba, grapefruit, grapefruit juice) from within 30 days prior to the first administration of IP until the end of the study.
14. Use of PPIs, histamine (H)2 blockers, potassium-competitive acid blockers, or locally-acting antacids within 8 weeks before the first dose of IP, or requiring these medications during the study (except for the planned use of rabeprazole specified in the protocol)
15. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP (and up until 14 days after the last dose of the IP).
16. Use of any IP or investigational medical device within 30 days prior to the first administration of IP, or 5 half lives of the product (whichever is the longest), and during the course of the study.
17. Positive toxicology screening panel (urine test including qualitative identification of amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, and tricyclic antidepressants), or alcohol breath test at Screening. Note: A single repeat test in the event of a false positive is permitted for the drug of abuse urine test at the discretion of the Investigator.
18. History of regular alcohol consumption defined as > 14 standard drinks per week or > 3 standard drinks on any single day (where 1 standard drink = 10 g of alcohol) within 3 months prior to Screening.
19. Unwilling or unable to abstain from the consumption of alcohol and caffeine containing food or drinks beginning 72 hours prior to the first administration of IP and until the end of the study.
20. Unwilling to abstain from cigarettes or nicotine-containing products (eg, cigars, vapes, nicotine patches) for at least 7 days prior to first IP administration through to the end of the study, or is considered to be dependent on nicotine at the discretion of the PI. Note: Participants that are considered light or social smokers (defined as ≤ 5 cigarettes per week) will be considered eligible for entry into the study but must also adhere to these restrictions.
21. Unwilling to refrain from strenuous exercise (including weightlifting) from 48 hours prior to each admission (on Day -1, Day 11, and Day 28), during the inpatient stays, and for 48 hours prior to any outpatient visit (including the EOS visit).
22. Unable or unwilling to consume a high-fat meal.
23. Pregnant or lactating.
24. Poor peripheral venous access.
25. Anything that the PI considers that would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VRN101099-Sequence A; Unit Dose: 40 milligram + 120 milligram capsules Route of Administration: Oral (Capsules) Participants will receive a total oral dose of 160 mg of the investigational product administered as two capsules taken together, consisting of one 40 mg capsule (size 4, white opaque) and one 120 mg capsule, to achieve the required 160 mg dose.	Drug: VRN101099; Type: Capsule form Route of administration: Oral
Experimental: VRN101099-Sequence B; Unit Dose: 40 milligram + 120 milligram capsules Route of Administration: Oral (Capsules) Participants will receive a total oral dose of 160 mg of the investigational product administered as two capsules taken together, consisting of one 40 mg capsule (size 4, white opaque) and one 120 mg capsule, to achieve the required 160 mg dose.	Drug: VRN101099; Type: Capsule form Route of administration: Oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma PK parameters- AUC0-inf (Area under the plasma concentration-time curve from time 0 extrapolated to infinity.)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- C24 (The concentration observed at 24 hours post-dose.)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- Cmax (Maximum observed plasma drug concentration (directly determined from the plasma concentration-time profiles).)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- Tmax (Time to maximum observed plasma drug concentration)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- AUC0-24 (Area under the plasma concentration-time curve, from time zero (time of dosing) to 24 hours post-dose with measurable analyte concentration, calculated by 'the linear up and log down' method)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- AUC0-last (Area under the plasma concentration-time curve, from time zero to the last time point with measurable analyte concentration)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Plasma PK parameters- AUC0-inf (Area under the plasma concentration-time curve from time 0 extrapolated to infinity)	The mixed model for repeated measures (MMRM) will be performed on the natural-log (ln)-transformed PK parameters	Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Area under the plasma concentration versus time curve (AUC) in the presence or absence of high-fat, high-calorie food.		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Peak Plasma Concentration (Cmax) in the presence or absence of high-fat, high-calorie food.		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Area under the plasma concentration versus time curve (AUC) in the presence or absence of Proton pump inhibitor (PPI) in fasting conditions (fasted PK data comparison in Period 3 and Period 2 for Sequence 2 participants).		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Peak Plasma Concentration (Cmax) in the presence or absence of Proton pump inhibitor (PPI) in fasting conditions (fasted PK data comparison in Period 3 and Period 2 for Sequence 2 participants).		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Area under the plasma concentration versus time curve (AUC) in the presence or absence of Proton pump inhibitor (PPI) in fed conditions (fed PK data comparison in Period 3 and Period 2 for Sequence 1 participants).		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40
Peak Plasma Concentration (Cmax) ratios in the presence or absence of Proton pump inhibitor (PPI) in fed conditions (fed PK data comparison in Period 3 and Period 2 for Sequence 1 participants).		Day 1,2,3,4,7,11,12,13,14,15,19,23,29,30,31,32,36,40

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of TEAEs		Day 1 to Day 41 (EOS-End of study visit)
Incidence of SAEs		Day 1 to Day 41 (EOS-End of study visit)
Number of participants with abnormal vital signs	Vital signs include tympanic body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. Vital signs are to be taken after the participant has rested in the supine position for ≥ 5 minutes. Vital signs will be measured in triplicates at approximately 2-minute intervals at Day 1, Day 12, and Day 29 (pre-dose). The averages of these triplicate measurements will be used to assess suitability for dosing as well as to determine if a repeat measurement is required.	Day 1 to Day 41 (EOS-End of study visit)
Number of participants with abnormal Physical examination findings	Complete physical examinations include general appearance, mouth/dental (if required), neck (including thyroid & nodes), cardiovascular, respiratory, gastrointestinal, renal, neurological, musculoskeletal, skin, other.	Day 1 to Day 41 (EOS-End of study visit)
Number of participants with abnormal laboratory tests results	Hematology, clinical chemistry, Coagulation and urinalysis parameters will be assessed at scheduled visits	Day 1 to Day 41 (EOS-End of study visit)
Number of participants with abnormal ECG readings	12 Lead ECG: Triplicate readings to be taken within 2 to 5 minutes of each other. ECGs are to be taken after the participant has rested in the supine position for ≥ 5 minutes.	Day 1 to Day 41 (EOS-End of study visit)

Collaborators and Investigators

• Sponsor: Voronoi, Inc

Study record dates

Study Major Dates

• Study Start (Estimated): May 12, 2026
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: April 9, 2026
• First Submitted That Met QC Criteria: April 19, 2026
• First Posted (Actual): April 24, 2026

Study Record Updates

• Last Update Posted (Actual): April 24, 2026
• Last Update Submitted That Met QC Criteria: April 19, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: VRN101099-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No